Slide 1: Full Year Results June 2020 – Investor Presentation
Full Year Results June 2020 – Investor Presentation 5 October 2020 Copyright © Physiomics Plc 2020 - www.physiomics.co.uk
Slide 2: Disclaimer
Disclaimer The information contained in this presentation ("Presentation") has been prepared by Physiomics Plc (the "Company"). This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 (" FSMA"). This Presentation sh
Slide 3: Physiomics is focused on modelling cancer
Physiomics is focused on modelling cancer Knowledge of PK/ PD* modelling cancer using Virtual Tumour™ Ability to access Understanding of AI/ and curate data machine learning Slide 3 Copyright © Physiomics Plc 2020 - www.physiomics.co.uk *Pharmacokinetic/ pharmacodynamic
Slide 4: We work with biotech/ pharma and develop personalised oncology tools
We work with biotech/ pharma and develop personalised oncology tools Supporting oncology R&D Personalised oncology • Analytical and modelling support • Grant funded by Innovate UK for oncology pre-clinical • Potential to predict toxicity development and response to treatment for individuals or group
Slide 5: We've completed over 70 commercial and grant funded projects
We’ve completed over 70 commercial and grant funded projects Big pharma Merck, Astellas, MSD, Lilly, Bayer and others Grants Innovate UK, EU-FP6 >80 Biotech/ Midcap Bicycle Therapeutics, (TEMPO), Carbon Trust projects Cellcentric, Convert Pharma completed and others Academic Medicines Discovery Cata
Slide 6: How we support development
How we support development Recommend efficacy/ toxicity trade-offs ✓ Recommend experiments to confirm and refine hypotheses if desired ✓ Recommend combination partner agent for proprietary in-house asset ✓ Assess efficacy of existing assets in new indications ✓ Predict biologically effective dose in
Slide 7: Selected financial highlights: year ending Jun 2020
Selected financial highlights: year ending 30 Jun 2020 • Total income (revenue and grant income) increased 7% to £841,649 (2019: £783,101), the highest in the Company’s history • The operating loss decreased 33% to £134,385 (2019: £201,219) • The loss after taxation decreased 38% to £64,424 (2019: £
Slide 8: Selected operational highlights: year ending Jun 2020
Selected operational highlights: year ending 30 Jun 2020 • Renewal of agreement with Merck KGaA in December 2019 • Repeat contracts with clients CellCentric and Bicycle Therapeutics • Award of NIHR grant to fund clinical study relating to Physiomics’ personalised dosing tool for prostate cancer and
Slide 9: Continued revenue growth and good cash management
Continued revenue growth and good cash management Slide 9 Copyright © Physiomics Plc 2020 - www.physiomics.co.uk
Slide 10: Evolving our consulting business model
Evolving our consulting business model • Continue to drive our main commercial business of consulting services which rely substantially on our proprietary Virtual Tumour™ technology • Explore models complementary to consulting including: • The embedding of our technology as part of a broader offerin
Slide 11: Expanding into Personalised Oncology
Expanding into Personalised Oncology The Drivers The Physiomics Solution • Significant unmet need for • Tool to optimise dosing of $ improved efficacy/ reduced toxicity • Huge cost pressures in health docetaxel in prostate cancer • Helps balance efficacy and toxicity for individual patients system F
Slide 12: Strategy: Build on successful full year and accelerate growth
Strategy: Build on successful full year and accelerate growth • Form close partnerships with customers, attract repeat business • Diversify the customer base by working with a variety of commercial and not-for-profit clients • Broaden our geographical presence in Europe and North America • Work with
Slide 13: Contacts
Contacts: • Physiomics plc, info@physiomics.co.uk • Hybridan LLP, Broker, research@hybridan.com Copyright © Physiomics Plc 2020 - www.physiomics.co.uk
Slide 14: Income Statement for the year ended 30 June 2020
Income Statement for the year ended 30 June 2020 Slide 14 Copyright © Physiomics Plc 2020 - www.physiomics.co.uk
Slide 15: Statement of Financial Position as at 30 June 2020
Statement of Financial Position as at 30 June 2020 Slide 15 Copyright © Physiomics Plc 2020 - www.physiomics.co.uk
Slide 16: Cash Flow Statement for the year ended 30 June 2020
Cash Flow Statement for the year ended 30 June 2020 Slide 16 Copyright © Physiomics Plc 2020 - www.physiomics.co.uk
Slide 17: Board of directors
Board of directors • Dr Paul Harper (Non-Executive Chairman) has over 35 years' experience in the life sciences industry covering both drug development and medical devices. He was a non-executive director of Reneuron Holdings Plc, an AIM quoted company. Paul has served as Chairman of Oval Medical Te